Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

To further characterize the safety of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer, we analyzed adverse events of clinical interest in the phase II VISION trial (N =255). The most frequent adverse events were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals. Introduction: The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors. Patients and Methods: Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to composite categories (edema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting), for patients with METex14 skipping NSCLC in the phase II VISION trial. Results: Of 255 patients analyzed (median age: 72 years), edema, the most common AECI, was reported in 69.8% (grade 3, 9.4%; grade 4, 0%). Median time to first edema onset was 7.9 weeks (range: 0.1-58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.9% (grade 3, 5.5%); pleural effusion, 13.3% (grade >= 3, 5.1%); creatinine increase, 25.9% (grade 3, 0.4%); nausea, 26,7% (grade 3, 0.8%), diarrhea, 26.3% (grade 3, 0.4%), vomiting 12.9% (grade 3, 1.2%), and ALT/AST increase, 12.2% (grade >= 3, 3.1%). GI AEs typically occurred early and resolved in the first weeks. Conclusion: Tepotinib was well tolerated in the largest trial of a MET inhibitor in METex14 skipping NSCLC. The most frequent AEs were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals in this elderly population. (C) 2022 The Authors. Published by Elsevier Inc.

Automated summary

The study demonstrated the safety and tolerability of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer. Adverse events were mostly mild/moderate and manageable, with few withdrawals.